Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1440-1450

  Small, Eric J ^a   Meyer, Mark ^a   Marshall, M Ernest ^a   Reyno, Leonard M ^a   Meyers, Frederick J ^a   Natale, Ronald B ^a   Lenehan, Peter F ^a   Chen, Liang ^a   Slichenmyer, William J ^a   Eisenberger, Mario ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MORPHINE; OPIATE AGONIST; SURAMIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

EID: 0034128221     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1440     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Garnick MB: Prostate cancer: Screening, diagnosis, and management. Ann Intern Med 118:804-818, 1993
3. Small EJ, Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 15:382-388, 1997
4. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
5. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
6. Kelly WK, Scher HI, Mazumdar M: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
7. Smith DC, Dunn RL, Strawderman MS, et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835-1843, 1998
8. Sridhara R, Eisenberger M, Sinibaldi V, et al: Evaluation of prostate specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995
9. Fossa S, Aaronson N, Newling D: Quality of life and treatment of hormone-resistant metastatic prostate cancer. Eur J Cancer 26:1133-1136, 1990
10. Scher HI, Kelly WK: Suramin: Defining the role in the clinic, in Devita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology (ed 7). Philadelphia, PA, Lippincott, 1993, pp 1-16
11. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995
12. Reyno LM, Egorin MJ, Eisenberger MA, et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995
13. Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995
14. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
15. Kelly WK, Scher HI, Mazumdar M, et al: Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 13:2214-2222, 1995
16. Rosen PJ, Mendoza EF, Landaw EM, et al: Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy. J Clin Oncol 14:1626-1636, 1996
17. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
18. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
19. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 76:1428-1434, 1995
20. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
21. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
22. Kornblith AB, Hollis DR, Zuckerman E, et al: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11:2081-2089, 1993
23. O'Brien PC: Procedures for comparing samples with multiple endpoints. Biometrics 40:1079-1087, 1984
24. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Lowitt MH, Eisenberger ME, Sina B, Kao GF: Cutaneous eruptions from suramin. Arch Dermatol 131:1147-1153, 1995
27. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
28. Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
29. Thalmann GN, Sikes RA, Chang S-M, et al: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88:794-801, 1996
30. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 17:3461-3467, 1999
31. Stein CA, LaRocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989
32. Dawson NA, Figg WD, Cooper Mr, et al: Phase II trial of suramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 15:1470-1477, 1997
33. Tu SM, Pagliaro LC, Banks ME, et al: Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 4:1193-1201, 1998